| This article has been cited by |
| 1 | Cell-Based Therapies for Stroke: Are We There Yet? | |
| Mirja Krause,Thanh G. Phan,Henry Ma,Christopher G. Sobey,Rebecca Lim |
| Frontiers in Neurology.2019;10() |
| [DOI] |
|
| 2 | Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan | |
| Mitsuhiro Rokuda,Naoki Matsumaru,Katsura Tsukamoto |
| Clinical Therapeutics.2018;40(2)284 |
| [DOI] |
|
| 3 | Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015–2016 | |
| Yao Qiao,G Caleb Alexander,Thomas J Moore |
| Clinical Trials.2019;16(3)329 |
| [DOI] |
|
| 4 | Regional efficacy evaluation in multi-regional clinical trials using a discounting factor weighted
Z
test | |
| Xuanxuan Yu,Lixin Cai,Hao Yu,Zihang Zhong,Min Yang,Jingwei Wu,Jianling Bai |
| Pharmaceutical Statistics.2023;22(2)266 |
| [DOI] |
|
| 5 | The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview | |
| Bruna Aparecida Souza Machado,Katharine Valéria Saraiva Hodel,Larissa Moraes dos Santos Fonseca,Luís Alberto Bręda Mascarenhas,Leone Peter Correia da Silva Andrade,Vinícius Pinto Costa Rocha,Milena Botelho Pereira Soares,Peter Berglund,Malcolm S. Duthie,Steven G. Reed,Roberto Badaró |
| Vaccines.2021;9(11)1345 |
| [DOI] |
|
| 6 | The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview | |
| Saisai Wang |
| Vaccines.2020;5(11)81 |
| [DOI] |
|
| 7 | Cross-Border Access to Clinical Trials in the EU: Exploratory Study on Needs and Reality | |
| Teodora Lalova,Cristina Padeanu,Anastassia Negrouk,Denis Lacombe,Jan Geissler,Ingrid Klingmann,Isabelle Huys |
| Frontiers in Medicine.2020;7(11)81 |
| [DOI] |
|
| 8 | Design and Implementation of Medical Searching System Based on Microservices and Serverless Architectures | |
| Jawad Sadek,Dawn Craig,Michael Trenell |
| Procedia Computer Science.2022;196(11)615 |
| [DOI] |
|
| 9 | Ethical Considerations in Clinical Trials for Disorders of Consciousness | |
| Michael J. Young,Yelena G. Bodien,Brian L. Edlow |
| Brain Sciences.2022;12(2)211 |
| [DOI] |
|
| 10 | Perspectives on Adopting the Guideline for Multi-regional Clinical Trials in Korea: A Multi-stakeholder Survey | |
| Minji Sohn,Yun-Kyoung Song,Ah Young Jeon,Jung Mi Oh,In-Wha Kim |
| Korean Journal of Clinical Pharmacy.2019;29(4)267 |
| [DOI] |
|
| 11 | Hierarchical Generalized Linear Models for Multiregional Clinical Trials | |
| Junhui Park,Seung-Ho Kang |
| Statistics in Biopharmaceutical Research.2022;14(3)358 |
| [DOI] |
|
| 12 | A Comparison of Safety Information in Drug Labeling at the Initial Approval of New Drugs Approved Both in Japan and the United States | |
| Yuko Hoshino,Mamoru Narukawa |
| Therapeutic Innovation & Regulatory Science.2022;56(5)839 |
| [DOI] |
|
| 13 | The progression of clinical trials in Indonesia: an observational study of records from clinical trial registries databases | |
| Marlinang Diarta Siburian,Sifa Marie Joelle Muchanga,Antonio Fredelindo Dela Resma Villanueva,Rianto Setiabudy,Iiyama Tatsuo |
| Global Health Journal.2020;4(3)87 |
| [DOI] |
|
| 14 | Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials | |
| Satoshi Ushijima,Naoki Matsumaru,Katsura Tsukamoto |
| Pharmaceutical Medicine.2021;35(4)253 |
| [DOI] |
|
| 15 | Investigator-initiated clinical trials in the Czech Republic - overview for 2004-2007 | |
| Lenka Horavová,Katerina Nebeská,Jana Merhautová,Regina Demlová,Lenka Soucková |
| Klinická farmakologie a farmacie.2019;32(4)3 |
| [DOI] |
|
| 16 | Investigator-initiated clinical trials in the Czech Republic - overview for 2004-2007 | |
| Zhaoling Meng |
| Klinická farmakologie a farmacie.2022;32(4)169 |
| [DOI] |
|
| 17 | Acceleration of rare disease therapeutic development: a case study of AGIL-AADC | |
| Sonya Das,Samuel Huang,Andrew W. Lo |
| Drug Discovery Today.2019;24(3)678 |
| [DOI] |
|
| 18 | A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-specific clinical success rates | |
| Jonathan Dando,Maximilian Lebmeier |
| Journal of Innovation and Entrepreneurship.2020;9(1)678 |
| [DOI] |
|
| 19 | Machine Learning Prediction of Clinical Trial Operational Efficiency | |
| Kevin Wu,Eric Wu,Michael DAndrea,Nandini Chitale,Melody Lim,Marek Dabrowski,Klaudia Kantor,Hanoor Rangi,Ruishan Liu,Marius Garmhausen,Navdeep Pal,Chris Harbron,Shemra Rizzo,Ryan Copping,James Zou |
| The AAPS Journal.2022;24(3)678 |
| [DOI] |
|
| 20 | Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials | |
| Marie-Noëlle Billard,Joanne Wildenbeest,Louis J. Bont,Harish Nair,John P. McCracken,Katrien Oude Rengerink,Katrien Marie-Noelle Billard,Katrien Oude Rengerink,Louis Bont,Joanne Wildenbeest,Harish Nair,Harry Campbell,Philippe Beutels,Peter Openshaw,Andrew Pollard,Federico Martinon-Torres,Terho Heikkinen,Adam Meijer,Thea Křlsen Fischer,Maarten van den Berge,Carlo Giaquinto,Jeroen Aerssens,Michael Abram,Kena Swanson,Clarisse Demont,Scott Gallichan,Veena Kumar,Sonia Stoszek,Eva Molero |
| Journal of Clinical Epidemiology.2022;147(3)11 |
| [DOI] |
|
| 21 | Indian Biosimilars and Vaccines at Crossroads–Replicating the Success of Pharmagenerics | |
| Sunita Panda,Puneet Kumar Singh,Snehasish Mishra,Sagnik Mitra,Priyabrata Pattnaik,Sanjib Das Adhikary,Ranjan K. Mohapatra |
| Vaccines.2023;11(1)110 |
| [DOI] |
|
| 22 | Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency | |
| Jenn W. Sellers,Camelia M. Mihaescu,Kassa Ayalew,Phillip D. Kronstein,Bei Yu,Yang-Min Ning,Miguel Rodriguez,LaKisha Williams,Ni A. Khin |
| Therapeutic Innovation & Regulatory Science.2022;56(5)753 |
| [DOI] |
|
| 23 | Regulations and Guidelines for Planning and Design of Multi-regional Clinical Trials | |
| Yun-Kyoung Song,Minji Sohn,Ah Young Jeon,Jae Hyun Kim,Eunhee Ji,Jung Mi Oh,In-Wha Kim |
| Korean Journal of Clinical Pharmacy.2018;28(2)146 |
| [DOI] |
|
| 24 | Strategic inclusion of regions in multiregional clinical trials | |
| Seung Yeon Song,Deborah Chee,EunYoung Kim |
| Clinical Trials.2019;16(1)98 |
| [DOI] |
|
| 25 | A Cross-sectional literature survey showed the reporting quality of multicenter randomized controlled trials should be improved | |
| Xuan Zhang,Wai Ching Lam,Fan Liu,Mengdan Li,Lin Zhang,Weifeng Xiong,Xiaohan Zhou,Ran Tian,Chongya Dong,Chen Yao,David Moher,Zhaoxiang Bian |
| Journal of Clinical Epidemiology.2021;137(1)250 |
| [DOI] |
|
| 26 | A Cross-sectional literature survey showed the reporting quality of multicenter randomized controlled trials should be improved | |
| Basant Amarji,Sara Nidal Abed,Ujjawal Bairagi,Pran Kishore Deb,Omar Al-Attraqchi,Anup Avijit Choudhury,Rakesh K. Tekade |
| Journal of Clinical Epidemiology.2018;137(1)637 |
| [DOI] |
|
| 27 | Lag Time for New Innovative, First-in-Class, Drug Approval in Japan | |
| Takayuki Miyazaki,Michiyuki Komiyama,Naoki Matsumaru,Hideki Maeda,Katsura Tsukamoto |
| Biological and Pharmaceutical Bulletin.2022;45(4)477 |
| [DOI] |
|
| 28 | Comparative evidence on harms in pediatric randomized clinical trials from less developed versus more developed countries is limited | |
| Dario Tedesco,Mufiza Farid-Kapadia,Martin Offringa,Zulfiqar A. Bhutta,Yvonne Maldonado,John P.A. Ioannidis,Despina G. Contopoulos-Ioannidis |
| Journal of Clinical Epidemiology.2018;95(4)63 |
| [DOI] |
|
